Recombinant monoclonal antibody to EGFR. Tomuzotuximab is a chimeric monoclonal antibody that can be potentially used in the treatment of Cancers, head and neck, Solid tumors.
Figure 1 Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end of infusion.
The dotted line indicates the 50 µg/mL trough level. Tomuzotuximab serum levels were above 50 µg/mL 1 week after the second infusion in four out of five patients who received 720 mg and 1 week after the first infusion in all three patients who received 900 mg tomuzotuximab.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Tomuzotuximab